Men taking Low-T therapy can rest easy. New research by the University of Texas Medical Branch at Galveston has found no link between testosterone therapy and blood clots.

The study, published in the journal Mayo Clinic Proceedings, tracked more than 30,000 middle-aged and older men and found those receiving testosterone therapy were not at increased risk for venous thromboembolism — where blood clots form in the veins and cause blockages.

"In 2014, the Federal Drug Administration required manufacturers to add a warning about potential risks of VTE to the label of all approved testosterone products," said lead researcher Jacques Baillargeon, professor of epidemiology in the department of preventive medicine and community health.

"The warning, however, is based primarily on post-marketing drug surveillance and case reports. To date, there have been no published comparative, large-scale studies examining the association of testosterone therapy and the risk of VTE."

The new case-control study tracked men from 2007 to 2012 determined having a prescription for testosterone therapy was not associated with an increased risk of VTE.

In addition, none of the specific routes of administration examined — topical creams, transdermal patches, or intramuscular injections — were associated with an increased risk.

"It is important to acknowledge, for a man who has medically-diagnosed low testosterone, that there are clear risks to not receiving testosterone therapy, including osteoporosis, sexual dysfunction, increased amounts of fat tissue, decreased lean muscle mass, possible metabolic syndrome, and cardiovascular disease," said Baillargeon.

"It's also important to note that further research needs to be conducted to rigorously assess the long-term risks of testosterone therapy.